Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
We also have skilled researchers that work persistently to develop novel cost-effective production solutions
AcetylL
Med Toxicol Adverse Drug Exp 3(6):499504 Friedheim E, Graziano JH, Popovac D, Dragovic D, Kaul B (1978) Treatment of lead poisoning by 2,3-dimercaptosuccinic acid
Component-Level Trial Findings CJC-1295 (without DAC, modified GRF 1-29) Phase 1 and Phase 2 work described: Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683) IGF-1 elevation of 1.5-3x baseline at 1-2 weeks Mild facial flushing post-injection in some participants No serious adverse events at studied doses CJC-1295 with DAC The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683)
BPC-157, Body Protection Compound-157, , (BPC),
Armour further warns us of Melanotan's dangers
